Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications.

Rowe SP, Gorin MA, Pomper MG.

Annu Rev Med. 2019 Jan 27;70:461-477. doi: 10.1146/annurev-med-062117-073027.

PMID:
30691373
2.

PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.

Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):223-30. doi: 10.1038/pcan.2016.13. Epub 2016 May 3. Review.

3.

Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms.

Salas Fragomeni RA, Amir T, Sheikhbahaei S, Harvey SC, Javadi MS, Solnes LB, Kiess AP, Allaf ME, Pomper MG, Gorin MA, Rowe SP.

J Nucl Med. 2018 Jun;59(6):871-877. doi: 10.2967/jnumed.117.203570. Epub 2018 Mar 15.

PMID:
29545375
4.

PSMA PET and Radionuclide Therapy in Prostate Cancer.

Bouchelouche K, Turkbey B, Choyke PL.

Semin Nucl Med. 2016 Nov;46(6):522-535. doi: 10.1053/j.semnuclmed.2016.07.006. Epub 2016 Sep 3. Review.

5.

New aspects of molecular imaging in prostate cancer.

Ceci F, Castellucci P, Cerci JJ, Fanti S.

Methods. 2017 Nov 1;130:36-41. doi: 10.1016/j.ymeth.2017.07.009. Epub 2017 Jul 13. Review.

PMID:
28711565
6.

Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.

Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, Cho SY, Pomper MG, Allaf ME.

Ann Nucl Med. 2015 Dec;29(10):877-82. doi: 10.1007/s12149-015-1017-z. Epub 2015 Aug 19.

7.

PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

Mease RC, Foss CA, Pomper MG.

Curr Top Med Chem. 2013;13(8):951-62. Review.

8.

Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.

Hofman MS, Hicks RJ, Maurer T, Eiber M.

Radiographics. 2018 Jan-Feb;38(1):200-217. doi: 10.1148/rg.2018170108. Review.

PMID:
29320333
9.

New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.

Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, Stief C, Thalmann GN, Picchio M.

Eur Urol. 2016 Jul;70(1):161-175. doi: 10.1016/j.eururo.2016.01.029. Epub 2016 Feb 2. Review.

PMID:
26850970
10.

A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).

Ahn T, Roberts MJ, Abduljabar A, Joshi A, Perera M, Rhee H, Wood S, Vela I.

Mol Imaging Biol. 2019 Jan 7. doi: 10.1007/s11307-018-01307-0. [Epub ahead of print]

PMID:
30617728
11.

68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?

Witkowska-Patena E, Mazurek A, Dziuk M.

Cent European J Urol. 2017;70(1):37-43. doi: 10.5173/ceju.2017.947. Epub 2017 Jan 11. Review.

12.

Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.

Arsenault F, Beauregard JM, Pouliot F.

Curr Opin Support Palliat Care. 2018 Sep;12(3):359-365. doi: 10.1097/SPC.0000000000000357.

PMID:
29939893
13.

Utility of 68 Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma.

Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS.

J Med Imaging Radiat Oncol. 2017 Jun;61(3):372-378. doi: 10.1111/1754-9485.12590. Epub 2017 Jan 24. Review.

PMID:
28116853
14.

123I-Labeled (S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedoic acid.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2009 Sep 29 [updated 2009 Nov 24].

15.

123I-Labeled (S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl) ureido)pentyl)ureido)pentanedoic acid.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2009 Sep 29 [updated 2009 Nov 24].

16.

Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers.

Cuccurullo V, Di Stasio GD, Mansi L.

World J Nucl Med. 2018 Apr-Jun;17(2):70-78. doi: 10.4103/wjnm.WJNM_54_17. Review.

17.

Imaging of Prostate-Specific Membrane Antigen Using [18F]DCFPyL.

Rowe SP, Gorin MA, Pomper MG.

PET Clin. 2017 Jul;12(3):289-296. doi: 10.1016/j.cpet.2017.02.006. Epub 2017 Apr 1. Review.

PMID:
28576167
18.

[Significance of PSMA imaging in prostate cancer].

Gasch C, Düwel C, Kopka K, Kratochwil C, Vinsensia M, Eiber M, Maurer T, Haberkorn U, Hadaschik B, Giesel FL.

Urologe A. 2017 Jan;56(1):3-12. doi: 10.1007/s00120-016-0293-0. German.

PMID:
28005153
19.

Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.

Rowe SP, Drzezga A, Neumaier B, Dietlein M, Gorin MA, Zalutsky MR, Pomper MG.

J Nucl Med. 2016 Oct;57(Suppl 3):90S-96S. Review.

20.

PET/CT With 68Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications.

Giovacchini G, Giovannini E, Riondato M, Ciarmiello A.

Curr Radiopharm. 2018;11(1):4-13. doi: 10.2174/1874471010666171101121803. Review.

PMID:
29090673

Supplemental Content

Support Center